Florence Thicklin
Overview
Explore the profile of Florence Thicklin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
127
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rothman R, Stewart T, Mourad A, Boulware D, McCarthy M, Thicklin F, et al.
JAMA Netw Open
. 2024 Oct;
7(10):e2439332.
PMID: 39422912
Importance: The effect of montelukast in reducing symptom duration among outpatients with mild to moderate COVID-19 is uncertain. Objective: To assess the effectiveness of montelukast compared with placebo in treating...
2.
Rothman R, Stewart T, Mourad A, Boulware D, McCarthy M, Thicklin F, et al.
medRxiv
. 2024 May;
PMID: 38798524
Importance: The effect of montelukast in reducing symptom duration among outpatients with mild to moderate coronavirus disease 2019 (COVID-19) is uncertain. Objective: To assess the effectiveness of montelukast compared with...
3.
Hamm M, Arnold J, Denson J, Edwards T, Merritt G, McCarthy M, et al.
J Clin Transl Sci
. 2024 Jan;
7(1):e264.
PMID: 38229896
Introduction: Engaging patients, caregivers, and other stakeholders to help guide the research process is a cornerstone of patient-centered research. Lived expertise may help ensure the relevance of research questions, promote...
4.
Stewart T, Rebolledo P, Mourad A, Lindsell C, Boulware D, McCarthy M, et al.
JAMA
. 2023 Nov;
330(24):2354-2363.
PMID: 37976072
Importance: The effect of higher-dose fluvoxamine in reducing symptom duration among outpatients with mild to moderate COVID-19 remains uncertain. Objective: To assess the effectiveness of fluvoxamine, 100 mg twice daily,...
5.
Boulware D, Lindsell C, Stewart T, Hernandez A, Collins S, McCarthy M, et al.
N Engl J Med
. 2023 Sep;
389(12):1085-1095.
PMID: 37733308
Background: The effectiveness of inhaled glucocorticoids in shortening the time to symptom resolution or preventing hospitalization or death among outpatients with mild-to-moderate coronavirus disease 2019 (Covid-19) is unclear. Methods: We...
6.
Naggie S, Boulware D, Lindsell C, Stewart T, Slandzicki A, Lim S, et al.
JAMA
. 2023 Feb;
329(11):888-897.
PMID: 36807465
Importance: It is unknown whether ivermectin, with a maximum targeted dose of 600 μg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate COVID-19. Objective: To evaluate...
7.
McCarthy M, Naggie S, Boulware D, Lindsell C, Stewart T, Felker G, et al.
JAMA
. 2023 Jan;
329(4):296-305.
PMID: 36633838
Importance: The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients with mild to moderate symptomatic COVID-19 is unclear. Objective: To evaluate the efficacy of low-dose fluvoxamine...
8.
Naggie S, Boulware D, Lindsell C, Stewart T, Lim S, Cohen J, et al.
medRxiv
. 2022 Dec;
PMID: 36561174
Background: Whether ivermectin, with a maximum targeted dose of 600 μg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate coronavirus disease 2019 (COVID-19) remains unknown. Our...
9.
McCarthy M, Naggie S, Boulware D, Lindsell C, Stewart T, Felker G, et al.
medRxiv
. 2022 Oct;
PMID: 36299427
Background: The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic coronavirus disease 2019 (COVID-19) is unclear. Design: ACTIV-6...
10.
Naggie S, Boulware D, Lindsell C, Stewart T, Gentile N, Collins S, et al.
JAMA
. 2022 Oct;
328(16):1595-1603.
PMID: 36269852
Importance: The effectiveness of ivermectin to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic COVID-19 is unknown. Objective: To evaluate the efficacy...